Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

NasdaqPulse Apr. 8 at 4:59 PM

$GNPX setting up as a classic high-risk / high-reward biotech watch 👉Click to view @NasdaqPulse for timely updates amid the volatility. Stock is sitting near multi-year lows with RSI in the low 20s → deeply oversold territory. This is the kind of setup that’s triggered violent upside spikes in the past when news hits. What’s catching attention now: • Insider signal: Congressman Tim Moore has been actively buying shares • Near-term catalyst: AACR 2026 presentations next week • Ongoing lung cancer trials = potential data-driven momentum This name has a history of moving FAST when sentiment flips — especially with retail + catalyst alignment. But let’s be clear: Micro-cap biotech = binary risk. Data wins → upside. Data disappoints → downside. Right now it’s all about positioning into the catalyst window. Not for the faint of heart… but definitely one to watch.

0 · Reply

ACInvestorBlog Apr. 8 at 3:46 PM

$GNPX Genprex is a micro-cap biotech with a well-known history of violent upside moves on news and hype. The stock is currently deeply oversold (RSI in the low 20s), trading near multi-year lows. Adding fuel to the fire: Congressman Tim Moore has been actively buying shares in recent months, drawing fresh attention from retail traders. With upcoming catalysts like AACR 2026 data presentations and ongoing lung cancer trials, could the explosive rallies of the past happen again? Note: There is a catalyst next week at 2026 American Association for Cancer Research (AACR)

0 · Reply

Stockman189 Apr. 8 at 3:25 PM

$GNPX no ceasefire on this share price, ATM bombing raid continues…brutal!

0 · Reply

uptrend2025 Apr. 8 at 2:45 PM

$GNPX Even though the Conpany has around $21 million in cash less Q1 2026 burn, they have a huge ATM overhang of $58 million still remaining with no restrictions. I would wait until this dips further before jumping in. Abstracts for ACCR already published with data unless they present something new during the presentation.

0 · Reply

ACInvestorBlog Apr. 8 at 2:28 PM

$GNPX has a catalyst next week "Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting" Stock is extreme oversold and trading below cash levels (Est. Net Cash/Sh:1.83) Rep. Tim Moore has been buying this small name over the last months

1 · Reply

ACInvestorBlog Apr. 8 at 2:13 PM

$GNPX has a catalyst next week "Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting"

0 · Reply

daybaron Apr. 8 at 1:50 PM

$GNPX when's the next 40:1 reverse split?

0 · Reply

Jsubsierra Apr. 8 at 8:04 AM

$GNPX algun dia rebotara un +1000% y aun asi no recuperaré mis perdidas🤣

0 · Reply

MB76 Apr. 8 at 2:34 AM

$GNPX Serious question, why pay $1.40 when you can wait and have a chance to pay $.40? Hmm, enough said!!!

1 · Reply

MB76 Apr. 8 at 2:31 AM

$GNPX Just my opinion, this company should NOT have a publicly traded stock. CEO thinks this is his personal checking account and SHAREHOLDER value isn't in the vocab! RUN away from this scam. CEO should be ASHAMED!!!!!!!!!!!

1 · Reply

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:00 AM EDT - 4 weeks ago

Genprex to Participate at BIO Europe Spring 2026

Feb 23, 2026, 8:00 AM EST - 6 weeks ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Feb 10, 2026, 8:00 AM EST - 2 months ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Jan 7, 2026, 7:00 AM EST - 3 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 6, 2026, 7:00 AM EST - 3 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Nov 24, 2025, 7:00 AM EST - 4 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 19, 2025, 7:00 AM EST - 5 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 18, 2025, 7:00 AM EST - 5 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 4, 2025, 7:00 AM EST - 5 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Oct 28, 2025, 11:19 AM EDT - 5 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 7:00 AM EDT - 5 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 8:12 AM EDT - 5 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 5 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 8 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 8 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 10 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 10 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 11 months ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 11 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 11 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 1 year ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

NasdaqPulse Apr. 8 at 4:59 PM

0 · Reply

ACInvestorBlog Apr. 8 at 3:46 PM

0 · Reply

Stockman189 Apr. 8 at 3:25 PM

$GNPX no ceasefire on this share price, ATM bombing raid continues…brutal!

0 · Reply

uptrend2025 Apr. 8 at 2:45 PM

0 · Reply

ACInvestorBlog Apr. 8 at 2:28 PM

1 · Reply

ACInvestorBlog Apr. 8 at 2:13 PM

$GNPX has a catalyst next week "Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting"

0 · Reply

daybaron Apr. 8 at 1:50 PM

$GNPX when's the next 40:1 reverse split?

0 · Reply

Jsubsierra Apr. 8 at 8:04 AM

$GNPX algun dia rebotara un +1000% y aun asi no recuperaré mis perdidas🤣

0 · Reply

MB76 Apr. 8 at 2:34 AM

$GNPX Serious question, why pay $1.40 when you can wait and have a chance to pay $.40? Hmm, enough said!!!

1 · Reply

MB76 Apr. 8 at 2:31 AM

1 · Reply

MB76 Apr. 7 at 8:40 PM

$GNPX What are we learning? Just another pumper looking to pump for the dump!!!

0 · Reply

MakeMoney29 Apr. 7 at 6:52 PM

$GNPX what a shitty stock. Rodney and Ryan ran this one into the ground

0 · Reply

uptrend2025 Apr. 7 at 6:49 PM

$GNPX It still has ways to go. $0.75 I would be comfortable adding.

0 · Reply

Stockman189 Apr. 7 at 6:21 PM

$GNPX such a sad little existence, and now he’s taking a victory lap in a bear market…bless his little heart! 😆

1 · Reply

MB76 Apr. 7 at 6:11 PM

$GNPX Guess this pumping clown never learns! Hopefully people took caution and avoided. The blood is most likely NOT done here!

1 · Reply

Stockman189 Apr. 7 at 5:49 PM

$GNPX welp, at least we know what it feels like in Iran….share price getting bombed every day! 😂

0 · Reply

MB76 Apr. 7 at 10:56 AM

$GNPX $1 incoming!

1 · Reply

MB76 Apr. 7 at 10:56 AM

$GNPX Boy was I ever right! Run from this garbage!!!!!!!!

0 · Reply

P_etheris Apr. 7 at 10:27 AM

$GNPX This will be over $5 within 2 weeks☝️ I know, sounds ridiculous now🤷🏻‍♂️

1 · Reply

uptrend2025 Apr. 6 at 7:39 PM

$GNPX I very much like this Company but not at the current valuation. I would be comfortable adding $0.75-$1.00. ATM use was excessive according to 10K

0 · Reply

AshleySchaeffer_BMW Apr. 6 at 5:28 PM

$GNPX added another 10k down here. will move before long, shorts are playing with some very dangerous fire!!!

0 · Reply

BootyCheeks Apr. 6 at 3:31 PM

$GNPX what’s a good buy in price here?

1 · Reply

Market Cap	13.12M
Revenue (ttm)	0.00
Net Income (ttm)	-16.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	527,631
Avg Vol	853,702
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	8%
Beta	-0.69
Analysts	Strong Buy
Price Target	$7.50